Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio is on track to file an IND for their lead asset KRRO-121 in the second half of 2026, with potential to address a significant unmet need in the market for effective treatments for UCD and HE patients. With strong genetic evidence and promising preclinical data showcasing KRRO-121's ability to reduce high ammonia levels, the company has a solid foundation for their treatment approach. Furthermore, the established regulatory pathway for existing treatments in both UCD and HE provides a clear path for KRRO-121's development. With a potential blockbuster market opportunity of $1.5-2.0 billion, Korro Bio's stock is positioned for success.

Bears say

Korro Bio is a clinical stage biopharmaceutical company focusing on developing RNA-editing technology to treat genetic diseases with high unmet medical needs. However, the Company faces intense competition in the biotechnology and pharmaceutical industries and possesses limited financial resources and experience in the discovery and development of product candidates. The development of new treatment methods for these diseases by competitors could make Korro Bio's therapies non-competitive or obsolete, leading to significant risks for the Company's financial performance. Additionally, the Company is a development stage company and has not yet generated any revenue, requiring constant fundraising for its research and product development programs. These risks could negatively impact the Company's potential and valuation in the long-term.

KRRO has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 8 analysts, KRRO has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.